A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

Molecular Cancer Therapeutics

Volumn 8, Issue 10, 2009, Pages 2861-2871

  Schmidt, Michael M ^a   Wittrup, K Dane ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME; NANOPARTICLE;

ARTICLE; BINDING AFFINITY; CANCER THERAPY; CAPILLARY PERMEABILITY; COMPARTMENT MODEL; DIAGNOSTIC IMAGING; DRUG TARGETING; HUMAN; MOLECULAR DYNAMICS; MOLECULAR SIZE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; HUMANS; MICE; MODELS, BIOLOGICAL; MOLECULAR WEIGHT; NEOPLASMS; PERMEABILITY; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350234894     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0195     Document Type: Article

References (50)

1. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-763
2. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001;46:149-168
3. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci 2008;29:57-61.
4. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126-1136 (Pubitemid 41486394)
5. Zahnd C, Wyler E, Schwenk JM, et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 2007;369: 1015-1028 (Pubitemid 46754059)
6. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 2006; 66:4339-4348
7. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-171
8. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003;55: 1261-1277 (Pubitemid 37464561)
9. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006;98:335-344 (Pubitemid 43338213)
10. Krol A, Maresca J, Dewhirst MW, Yuan F. Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery. Cancer Res 1999;59:4136-4141 (Pubitemid 29393589)
11. Pluen A, Boucher Y, Ramanujan S, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A 2001;98:4628-4633 (Pubitemid 32295027)
12. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 2003;63:1288-1296
13. Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 2007;48: 995-999
14. Nugent LJ, Jain RK. Pore and fiber-matrix models for diffusive transport in normal and neoplastic tissues. Microvasc Res 1984;28:270-274
15. Paine PL, Scherr P. Drag coefficients for the movement of rigid spheres through liquid-filled cylindrical pores. Biophys J 1975;15: 1087-1091
16. Michel CC, Curry FE. Microvascular permeability. Physiol Rev 1999; 79:703-761
17. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 1989;37:77-104.
18. Qi Z, Whitt I, Mehta A, et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 2004;286:F590-6. (Pubitemid 38233654)
19. Deen WM, Lazzara MJ, Myers BD. Structural determinants of glomerular permeability. Am J Physiol Renal Physiol 2001;281:F579-96.
20. Yamada E. The fine structure of the renal glomerulus of the mouse. J Biophys Biochem Cytol 1955;1:551-566
21. Lazzara MJ, Deen WM. Effects of plasma proteins on sieving of tracer macromolecules in glomerular basement membrane. Am J Physiol Renal Physiol 2001;281:F860-8.
22. Kaneo Y, Uemura T, Tanaka T, Kanoh S. Polysaccharides as drug carriers: biodisposition of fluorescein-labeled dextrans in mice. Biol Pharm Bull 1997;20:181-187 (Pubitemid 27123170)
23. Kaliss N, Pressman D. Plasma and blood volumes of mouse organs, as determined with radioactive iodoproteins. Proc Soc Exp Biol Med 1950; 75:16-20.
24. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-3756
25. Nakaoka R, Tabata Y, Yamaoka T, Ikada Y. Prolongation of the serum half-life period of superoxide dismutase by poly(ethylene glycol) modification. J Control Release 1997;46:253-261 (Pubitemid 27132849)
26. Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res 2002;25:97-113.
27. Austin CD, De Maziere AM, Pisacane PI, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004;15:5268-5282
28. Karacay H, Ong GL, Hansen HJ, Griffiths GL, Goldenberg DM, Mattes MJ. Intracellular processing of 99Tcm-antibody conjugates. Nucl Med Commun 1998;19:971-979
29. Willuda J, Kubetzko S, Waibel R, Schubiger PA, Zangemeister-Wittke U, Pluckthun A. Tumor targeting of mono-, di-, and tetravalent anti-p185 (HER-2) miniantibodies multimerized by self-associating peptides. J Biol Chem 2001;276:14385-14392 (Pubitemid 37391829)
30. Kubetzko S, Balic E, Waibel R, Zangemeister-Wittke U, Pluckthun A. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J Biol Chem 2006;281: 35186-35201 (Pubitemid 46043248)
31. Tran T, Engfeldt T, Orlova A, et al. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 2007;18:1956-1964.
32. Tsai SW, Sun Y, Williams LE, Raubitschek AA, Wu AM, Shively JE. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem 2000;11:327-334 (Pubitemid 30324898)
33. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750-4755 (Pubitemid 32691886)
34. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11:812-818 (Pubitemid 44280021)
35. Green AJ, Johnson CJ, Adamson KL, Begent RH. Mathematical model of antibody targeting: important parameters defined using clinical data. Phys Med Biol 2001;46:1679-1693
36. Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother 2008;57:1879-1890
37. Williams LE, Wu AM, Yazaki PJ, et al. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother Radiopharm 2001;16:25-35.
38. Thomas GD, Chappell MJ, Dykes PW, et al. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res 1989;49:3290-3296
39. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an album-inbinding Fab, a novel tumor-targeting agent. Cancer Res 2007;67:254-261 (Pubitemid 46142782)
40. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823-834 (Pubitemid 46671186)
41. Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 2006;103:16436-16441 (Pubitemid 44715214)
42. Wicki A, Wild D, Storch D, et al. [Lys40(Ahx-DTPA-111In)NH2]- Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 2007;13: 3696-3705
43. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nano-particles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 2007;104:15549-15554 (Pubitemid 47502954)
44. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66: 6732-6740 (Pubitemid 44085631)
45. Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nano-particles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A 2008;105:2586-2591
46. Hilmas DE, Gillette EL. Morphometric analyses of the microvasculature of tumors during growth and after x-irradiation. Cancer 1974;33:103-110
47. Jackson TL, Lubkin SR, Siemers NO, Kerr DE, Senter PD, Murray JD. Mathematical and experimental analysis of localization of anti-tumour antibody- enzyme conjugates. Br J Cancer 1999;80:1747-1753
48. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 2008;14:2171-2179
49. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996;56:2123-2129 (Pubitemid 26119913)
50. Engfeldt T, Tran T, Orlova A, et al. (99m)Tc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 2007;34:1843-1853.